COST-EFFECTIVENESS OF ONCE-WEEKLY SEMAGLUTIDE 1 MG VS. CANAGLIFLOZIN 300 MG IN PATIENTS WITH TYPE 2 DIABETES IN A CANADIAN SETTING

被引：0
|
作者：
Liu, A. [1 ]
Bech, P. [1 ]
Fridhammar, A. [2 ]
Nilsson, A. [2 ]
Willis, M. [2 ]
Johansen, P. [3 ]
机构：
[1] Novo Nordisk Canada Inc, Mississauga, ON, Canada
[2] Swedish Inst Hlth Econ, Lund, Sweden
[3] Novo Nordisk AS, Soborg, Denmark
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB32
引用
收藏
页码：S114 / S114
页数：1
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS ANALYSIS OF ONCE-WEEKLY SEMAGLUTIDE VERSUS POLYETHYLENE GLYCOL LOXENATIDE FOR TREATMENT OF TYPE 2 DIABETES IN CHINA
    Liu, L.
    Zhen, R.
    Ung, C. O. L.
    Shen, Y.
    Zhang, Y.
    Han, S.
    Jia, R.
    Qiao, J.
    Hu, H.
    Guo, L.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S116 - S116
  • [32] The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China
    Shuyan Gu
    Jinghong Gu
    Xiaoyong Wang
    Xiaoling Wang
    Lu Li
    Hai Gu
    Biao Xu
    [J]. Health Economics Review, 14
  • [33] The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China
    Gu, Shuyan
    Gu, Jinghong
    Wang, Xiaoyong
    Wang, Xiaoling
    Li, Lu
    Gu, Hai
    Xu, Biao
    [J]. HEALTH ECONOMICS REVIEW, 2024, 14 (01)
  • [34] Once-weekly semaglutide vs existing once-weekly glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of Type 2 diabetes: Long-term cost-effectiveness analyses in the UK setting
    Viljoen, A.
    Hoxer, C. S.
    Johansen, P.
    Malkin, S. J. P.
    Hunt, B.
    Bain, S. C.
    [J]. DIABETIC MEDICINE, 2019, 36 : 134 - 134
  • [35] Effects of once-weekly semaglutide vs canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 trial
    McCrimmon, R. J.
    Catarig, A.
    Frias, J. P.
    Lausvig, N. L.
    le Roux, C. W.
    Thielke, D.
    Lingvay, I.
    [J]. DIABETOLOGIA, 2019, 62 : S29 - S29
  • [36] Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin
    Jose Gorgojo-Martinez, Juan
    Malkin, Samuel J. P.
    Martin, Virginia
    Hallen, Nino
    Hunt, Barnaby
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (02) : 193 - 203
  • [37] Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands (vol 7, e000705, 2019)
    Hunt, B.
    Malkin, S. J. P.
    Moes, R. G. J.
    [J]. BMJ OPEN DIABETES RESEARCH & CARE, 2019, 7 (01)
  • [38] Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States
    Neslusan, Cheryl
    Teschemaker, Anna
    Willis, Michael
    Johansen, Pierre
    Vo, Lien
    [J]. DIABETES THERAPY, 2018, 9 (02) : 565 - 581
  • [39] Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States
    Cheryl Neslusan
    Anna Teschemaker
    Michael Willis
    Pierre Johansen
    Lien Vo
    [J]. Diabetes Therapy, 2018, 9 : 565 - 581
  • [40] Once-Weekly Semaglutide 1mg vs. Empagliflozin 25mg as Add-On to Metformin Monotherapy in Patients with Type 2 Diabetes: A Meta-regression Analysis of Individual Patient Data
    Lingvay, Ildiko
    Catarig, Andrei-Mircea
    Sandberg, Anna
    Lawson, Jack
    Capehorn, Matthew
    Johansen, Pierre
    Shaw, Robert D.
    Paine, Abby
    [J]. DIABETES, 2020, 69
12345